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Mechanisms of Chemoefficacy 166 167
One mechanism by which chemotherapy agents exert their therapeutic effect is 168 by committing tumor cells to apoptosis [29, 30] . In comparison to other forms of cell 169 death, such as necrosis, apoptotic cell death is energy dependent, genetically controlled 170 and morphologically distinct (i.e., developing apoptotic bodies, cell shrinking and 171 nuclear condensation) (Figure 1 ) [31] . Apoptosis has been identified in primary breast 172 tumors treated with neoadjuvant chemotherapy in situ. Studies by Chang et al. (2000) 173 and Ellis et al. (1997) demonstrated that there was an increase in apoptosis in 174 responsive tumors and detected as early as 24 hours after the administration of 175 chemotherapy [32, 33] . Chang et al. (2000) showed that increased apoptosis was 176 linked to complete pathologic response where there was no residual or palpable 177 disease after therapy [32] . Buchholz et al. (2003) also measured the apoptotic activity 178 in breast tumors after 48 hours of chemotherapy. Patients who had a 25% increase in 179 the apoptotic activity had gone on to achieve pCR. The apoptotic activity was 180 significantly different to patients who did not achieve pCR (P<0.015) [34] . Although 181 only a small number of clinical studies have examined serial breast tumor biopsies to 182 measure apoptosis in situ, the findings to date have indicated agreement with 183 laboratory-based experiments for other tumor types in vitro [35] [36] [37] . 184
Alterations in the tumor's vascular organization are also important hallmarks of 185
chemoefficacy. An important property of malignancies is the abnormal vascular 186 architecture, which contributes to a spatially heterogeneous environment [38] 
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Conventional Imaging Methods 213
Conventional imaging from magnetic resonance imaging (MRI), computed 214 tomography (CT) and B-mode ultrasound (US) are used to measure tumor size changes 215 during NAC. Radiological response criteria are graded using RECIST 1.1 (Response 216
Criteria in Solid Tumors) guidelines [46] . However, major limitations for measuring 217 tumor size changes include: 1) dependency on user expertise to identify the lesion; 2) 218 distinguishing tumor boundaries on multiple scan planes in the case of MRI and CT; 3) 219 a change in the tumor's size may take several weeks before it is detectable, which limits 220 early detection and; 4) size measurements may be conflated with fibrosis, collagen, fatty 221 tissue and inflammation in the breast. 222
Quantitative imaging biomarkers addresses the limitations associated with 223 conventional imaging. Quantitative imaging biomarker techniques measure the 224 biological and functional tumor features previously outlined such as cell metabolism, cell 225 death and vascular reorganization. The overall purpose of investigating imaging 226 biomarkers in oncological studies is to achieve optimal accuracy of imaging biomarker 227 features with pathology endpoints such as pCR. Recent imaging methods are 228 described below and biomarker measurements are outlined in Table 1 therefore, serve to identify the extent of malignancies [51] . PET imaging is achieved 260 with the release of a gamma-ray photon that is detected by a photon-detection device 261 during radioactive decay, known as positron-electron annihilation. Another radiotracer 262 used in PET is the radionuclide 15 O-H 2 O, which is used to measure tumor blood flow; 263 where the distribution of water can be equated to blood activity in blood vessels [52] . 264
Previous work from Duch et al. (2009) showed that the intratreatment change in SUV 265 (DSUV, 2 cycles of chemotherapy) differentiated between pathologic response groups 266 (responders vs. non-responders) with a sensitivity of 77% and specificity of 80%, using 267 a cut-off value of 40% [53] . properties. Tumors are "stiffer" than the surrounding normal parenchyma because they 300 are comprised of densely populated and rapidly dividing cells, as well as increased 301 vasculature and fibroglandular components that alter its mechanical properties [62] [63] [64] . 302 13 Tissue stiffness can be measured in terms of tissue stress and strain using shear-wave 303 elastography or compression-based elastography. Evans et al. (2013) 
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Adopting imaging biomarkers as a decision-making tool in the clinic involves 365 several steps that originate with laboratory investigations and, following the translational 366 research pathway progress to clinical trials. Here, it is pertinent to discuss the current 367 demand from patients and clinicians for imaging biomarkers in the clinic, the 368 translational obstacles and how generalizable imaging biomarker models are for 369 measuring breast cancer response to NAC. The demand for imaging biomarkers has 
